

# Polymorphism in Pharmaceutical Solids

edited by  
Harry G. Brittain  
*Discovery Laboratories, Inc.*  
*Milford, New Jersey*



MARCEL DEKKER, INC.

NEW YORK • BASEL

P

**ISBN: 0-8247-0237-9**

This book is printed on acid-free paper.

**Headquarters**

Marcel Dekker, Inc.  
270 Madison Avenue, New York, NY 10016  
tel: 212-696-9000; fax: 212-685-4540

**Eastern Hemisphere Distribution**

Marcel Dekker AG  
Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland  
tel: 44-61-261-8482; fax: 44-61-261-8896

**World Wide Web**

<http://www.dekker.com>

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above.

**Copyright © 1999 by Marcel Dekker, Inc. All Rights Reserved.**

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Current printing (last digit):

10 9 8 7 6 5 4 3 2 1

**PRINTED IN THE UNITED STATES OF AMERICA**

# 8

## Effects of Pharmaceutical Processing on Drug Polymorphs and Solvates

**Harry G. Brittain**

*Discovery Laboratories, Inc.  
Milford, New Jersey*

**Eugene F. Fiese**

*Pfizer Central Research  
Groton, Connecticut*

I. INTRODUCTION	332
II. PRODUCTION AND STORAGE OF BULK DRUG SUBSTANCE	333
III. EFFECTS OF PARTICLE SIZE REDUCTION	334
IV. EFFECTS DUE TO GRANULATION	339
V. EFFECTS DUE TO DRYING	341
A. Changes in Crystalline Form Accompanying the Spray-Drying Process	343

B. Changes in the Crystalline State of Lyophilized Products	345
VI. EFFECTS DUE TO COMPRESSION	348
A. Changes in Crystal Form Effected by Compaction	348
B. Effects on Tablet Properties Associated with the Use of Different Crystal Forms	353
VII. SUMMARY	356
REFERENCES	358

## I. INTRODUCTION

In the previous chapters, the structural origin, energetics, and thermodynamics of polymorphs and solvates have been largely described for pure chemical entities. In most of the studies reported, the compounds were intentionally converted among various polymorphic forms for the purpose of study. In the present chapter, we will discuss the *unintentional* conversion of polymorphs and the desolvation of hydrates upon exposure to the energetics of pharmaceutical processing. Environments as harsh as 80°C and 100% RH for up to 6 h are not unusual during the routine manufacture of dosage forms. As previously noted, the various crystalline polymorphs frequently differ in their heats of fusion by as little as 1 kcal/mol, with the transition temperature being well below the boiling point of water. In the case of hydrates, removal of water from the crystal lattice requires more energy but is very much dependent on the temperature and humidity history of the sample.

In this chapter we will discuss the effects of pharmaceutical processing upon the crystalline state of polymorphic and solvate systems. Given the degree of attention lavished on drug substances that is required by solid-state pharmaceutical [1] and regulatory [2] concerns, it is only logical that an equivalent amount of attention be paid to processing issues. A variety of phase conversions are possible upon exposure to the energetic steps of bulk material storage, drying, milling, wet granulation, oven drying, and compaction. In this setting, an environment as harsh as 80°C and 100% RH for up to 12 h is not unusual,

and the mobility of water among the various components must be considered.

## II. PRODUCTION AND STORAGE OF BULK DRUG SUBSTANCE

The first processing opportunity to effect a change in polymorphic form or solvate nature is with the final crystallization step in the synthesis of the bulk drug substance. Crystallization is thought to occur by first forming hydrogen-bonded aggregates in the solution state, followed by the buildup of molecules to produce a crystal nucleus. A number of parameters are known to affect the crystallization process, including solvent composition and polarity, drug concentration and degree of supersaturation, temperature and cooling rate during the crystallization process, presence of seed crystals and/or nucleation sites, additives that influence crystal habit or add strain to the crystal lattice, agitation, pH, and the presence of a salt-forming molecule. It is evident that ample opportunity exists for the appearance of a polymorphic change when a process is scaled up, or moved to a new site, or run by a new operator.

Since the discovery chemist would have been able to make gram quantities of a quasi-crystalline drug substance, logic holds that the process chemist should be able to make kilograms of the same substance in a GMP manufacturing setting. While Mother Nature and equilibrium may have been fooled at the bench-top (where reaction steps are short and yield is improved through the use of anti solvents), longer processing times and improvements in purity usually mean that thermodynamic equilibrium will be achieved for the first time at the scale-up stage. On the other hand, the need for high yield frequently is the chief motivating force early in a development program, so even the first scale-up phase often fails to produce the thermodynamically preferred polymorph. Eventually, either at the first scale-up site or when the process is moved to a new site, the thermodynamically preferred form will appear. This observation has been attributed to Gay-Lussac, who noted that unstable forms are frequently obtained first, and that these subsequently transform to stable forms.

Eventually, either at the first scale-up site or when the process is moved to a new site, the thermodynamically preferred form will appear.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.